MeiraGTx is a clinical-stage gene therapy developer and manufacturer; its lead program, AAV2-hAQP1, is a one-time gene therapy for radiation-induced dry mouth, and none of its products is approved.
MeiraGTx's case rests on AAV2-hAQP1, a gene therapy injected into a salivary gland for radiation-induced xerostomia, which has Breakthrough Therapy designation after a 24-patient Phase 1 without placebo control. The randomized, placebo-controlled Phase 2 AQUAx2 is fully enrolled, and positive 12-month data in the second quarter of 2027 would support a BLA in mid-2027. Counting Oberland royalty financing and $95 million due from Hologen, MeiraGTx expects to be funded into the second half of 2028.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: AQUAx2 shows benefit over placebo
Does AAV2-hAQP1 improve dry mouth symptoms and salivary flow over placebo at 12 months?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
MeiraGTx expects 12-month data from the pivotal AQUAx2 trial of AAV2-hAQP1 in radiation-induced dry mouth in the second quarter of 2027, and plans regulatory filings for bota-vec in 2026
Radiation dry-mouth gene therapy with Breakthrough status pivots on a single pivotal readout, backed by $400M non-dilutive Oberland deal
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Eye diseases, Neurology and pain, Obesity, diabetes and heart disease
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
19 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.